FY2024 Earnings Estimate for GPCR Issued By Leerink Partnrs

Structure Therapeutics Inc. (NASDAQ:GPCR) – Equities research analysts at Leerink Partnrs dropped their FY2024 earnings estimates for Structure Therapeutics in a research report issued on Tuesday, December 3rd. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings of ($0.76) per share for the year, down from their prior estimate of ($0.59). The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.80) per share. Leerink Partnrs also issued estimates for Structure Therapeutics’ Q4 2024 earnings at ($0.20) EPS, FY2026 earnings at ($0.94) EPS, FY2027 earnings at ($0.85) EPS and FY2028 earnings at ($0.86) EPS.

Several other equities analysts have also recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. HC Wainwright assumed coverage on Structure Therapeutics in a research report on Wednesday. They issued a “buy” rating and a $80.00 target price for the company. Morgan Stanley initiated coverage on Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price target for the company. Finally, JMP Securities reduced their price objective on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research note on Friday, August 9th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $85.67.

Structure Therapeutics Price Performance

Shares of GPCR stock opened at $33.35 on Friday. The firm has a fifty day moving average of $37.29 and a two-hundred day moving average of $39.30. The firm has a market cap of $1.91 billion, a P/E ratio of -45.07 and a beta of -3.41. Structure Therapeutics has a 1-year low of $26.61 and a 1-year high of $62.85.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors have recently modified their holdings of GPCR. Point72 Asset Management L.P. grew its position in Structure Therapeutics by 196.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock worth $54,348,000 after purchasing an additional 820,589 shares during the last quarter. Janus Henderson Group PLC increased its position in Structure Therapeutics by 18.0% in the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after acquiring an additional 602,609 shares during the period. Vestal Point Capital LP raised its stake in Structure Therapeutics by 105.4% during the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $50,474,000 after acquiring an additional 590,000 shares in the last quarter. First Light Asset Management LLC boosted its position in Structure Therapeutics by 296.1% during the 2nd quarter. First Light Asset Management LLC now owns 590,647 shares of the company’s stock worth $23,195,000 after acquiring an additional 441,534 shares during the period. Finally, FMR LLC grew its stake in shares of Structure Therapeutics by 6.7% in the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after purchasing an additional 383,635 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.